At the helm of Helmholtz Health: Maike Sander
The Senate of the Helmholtz Association, Europe's largest research association, has elected Professor Maike Sander as Vice President to represent Helmholtz Health. This research field unites the expertise of over 9,000 researchers and specialists from six leading biomedical research centers within the Helmholtz Association. In addition to the Max Delbrück Center, Helmholtz Health comprises the German Cancer Research Center (DKFZ), the German Center for Neurodegenerative Diseases (DZNE), Helmholtz Munich, the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), and the Helmholtz Centre for Infection Research (HZI).
Advancements in technology and AI-driven innovations are set to transform medicine through precision prevention. Helmholtz Health is uniquely positioned to lead this transformation.
“Advancements in technology and AI-driven innovations are set to transform medicine through precision prevention.” says Sander, Scientific Director of the Max Delbrück Center. “Helmholtz Health is uniquely positioned to lead this transformation, leveraging cutting-edge technologies to enhance individual well-being and promote healthier, longer lives in an aging society.”
During her term, Sander aims to prioritize advancements in biomedical engineering, technology transfer, and population-based studies. “No single research group or center can tackle the major health challenges of our time,” she emphasizes. “The key lies in fostering interdisciplinary collaboration, bridging fields such as biomedicine, AI, and environmental research.”
Helmholtz Health offers unparalleled opportunities to build partnerships between science, industry, and society, enabling the joint development of innovative solutions for health research. “I am excited to help guide and nurture groundbreaking collaborations among Helmholtz Centers and beyond,” she says.
